Regenerative Medicine Market: Global Forecast to 2031

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3.1 REGENERATIVE MEDICINE MARKET OVERVIEW
3.2 REGENERATIVE MEDICINE MARKET, BY TYPE & REGION
3.3 REGENERATIVE MEDICINE MARKET: GEOGRAPHIC SNAPSHOT
3.4 REGENERATIVE MEDICINE MARKET SHARE, BY PRODUCT 2026 VS 2031

4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Expanding clinical pipeline and increasing commercialization of regenerative therapies
4.2.1.2 Broadening therapeutic applications of regenerative medicine
4.2.1.3 Increased investment and strategic partnerships
4.2.1.4 Advancing regulatory support for regenerative therapies
4.2.2 RESTRAINTS
4.2.2.1 High treatment costs and reimbursement constraints
4.2.2.2 Long-term safety and durability uncertainties
4.2.3 OPPORTUNITIES
4.2.3.1 Allogeneic and iPSC-derived "off-the-shelf" cell therapies
4.2.3.2 Clinical translation of tissue engineering and 3D bioprinting
4.2.4 CHALLENGES
4.2.4.1 Shortage of specialized manufacturing infrastructure and skilled personnel
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL REGENERATIVE MEDICINE MARKET
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER (2023-2025)
5.5.2 AVERAGE SELLING PRICE, BY REGION (2025)
5.6 KEY CONFERENCES & EVENTS
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8 INVESTMENT/FUNDING ACTIVITY
5.9 CASE STUDY ANALYSIS
5.10 IMPACT OF 2025 US TARIFFS—REGENERATIVE MEDICINE MARKET
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.10.4 IMPACT ON COUNTRIES/REGIONS
5.10.4.1 North America
5.10.4.2 Europe
5.10.4.3 Asia Pacific
5.10.5 IMPACT ON END-USE INDUSTRIES
5.10.5.1 Hospitals
5.10.5.2 Specialty clinics and cancer centers
5.10.5.3 Other specialty care settings

6.1 KEY EMERGING TECHNOLOGIES
6.1.1 AI-DRIVEN CELL & GENE THERAPY DEVELOPMENT
6.1.2 SMART BIOMATERIALS & INJECTABLE SCAFFOLDS
6.2 ADJACENT TECHNOLOGIES
6.2.1 ORGANOID & ORGAN-ON-CHIP TECHNOLOGIES
6.2.2 ADVANCED IMAGING & CELL CHARACTERIZATION TECHNOLOGIES
6.3 COMPLEMENTARY TECHNOLOGIES
6.3.1 BIOREACTORS & ADVANCED CELL CULTURE SYSTEMS
6.3.2 CELL EXPANSION & CELL PROCESSING TECHNOLOGIES
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PIPELINE ANALYSIS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GEN AI ON REGENERATIVE MEDICINE MARKET
6.7.1 TOP USE CASES AND MARKET POTENTIAL
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN REGENERATIVEMEDICINE MARKET
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACTON MARKET PLAYERS
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN REGENERATIVEMEDICINE MARKET

7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES,AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS

8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS,BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY

9.1 INTRODUCTION
9.2 CELL THERAPY
9.2.1 STEM CELL THERAPY
9.2.1.1 Cell transplantations
9.2.1.1.1 Potential of Allo-SCT in treating AML todrive segmental growth
9.2.1.2 Stem cell therapy products
9.2.1.2.1 Autologous therapy
9.2.1.2.1.1 Low risk of post-treatment complications to support segment growth
9.2.1.2.2 Allogeneic therapy
9.2.1.2.2.1 High potential in disease treatment to ensure demand and development
9.2.2 CELL-BASED IMMUNOTHERAPY
9.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth
9.3 GENE THERAPY
9.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET
9.4 TISSUE ENGINEERING
9.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET

10.1 INTRODUCTION
10.2 ONCOLOGY
10.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET
10.3 MUSCULOSKELETAL DISORDERS
10.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET
10.4 DERMATOLOGY & WOUND CARE
10.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET
10.5 CARDIOVASCULAR DISEASES
10.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH
10.6 OPHTHALMOLOGY
10.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH
10.7 NEUROLOGY
10.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH
10.8 OTHER THERAPEUTIC AREAS

11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.1.1 Rising number of pipeline products for regenerative medicineto drive market
11.2.2 CANADA
11.2.2.1 Rising government initiatives for regenerative medicine researchto drive market
11.3 EUROPE
11.3.1 GERMANY
11.3.1.1 Rising focus on clinical research and patent approvals to drive market
11.3.2 UK
11.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market
11.3.3 FRANCE
11.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline
11.3.4 ITALY
11.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market
11.3.5 SPAIN
11.3.5.1 Favorable regulatory environment to drive product pipeline
11.3.6 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 CHINA
11.4.1.1 Favorable government support for development of regenerative medicine to drive market
11.4.2 JAPAN
11.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies
11.4.3 INDIA
11.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth
11.4.4 SOUTH KOREA
11.4.4.1 Strong research base and availability of funds to support market growth
11.4.5 AUSTRALIA
11.4.5.1 Increasing incidence of sports injuries to support market growth
11.4.6 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 BRAZIL
11.5.1.1 Gradual increase in pharmaceutical R&D to support market growth
11.5.2 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS
11.7 AFRICA
11.7.1 RISING COLLABORATIONS TO SUPPORT MARKET GROWTH IN COMING YEARS

12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.3 REVENUE ANALYSIS, 2023-2025
12.4 MARKET SHARE ANALYSIS, 2025
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
12.5.5.1 Company footprint
12.5.6 REGION FOOTPRINT
12.5.7 PRODUCT FOOTPRINT
12.5.8 THERAPEUTIC AREA FOOTPRINT
12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
12.6.5.1 Detailed list of key startups/SMEs
12.6.5.2 Competitive benchmarking of startups/SMEs
12.7 COMPANY VALUATION AND FINANCIAL METRICS
12.7.1 VALUATION OF KEY PLAYERS
12.7.2 FINANCIAL METRICS OF KEY PLAYERS (PRODUCTS)
12.8 RAND/PRODUCT COMPARATIVE ANALYSIS
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSIONS

13.1 KEY MARKET PLAYERS
13.1.1 NOVARTIS AG
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Product approvals
13.1.1.3.2 Deals
13.1.1.3.3 Expansions
13.1.1.4 Analyst's view
13.1.1.4.1 Key Strengths/Right to win
13.1.1.4.2 Strategic choices made
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 GILEAD SCIENCES, INC.
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Product approvals
13.1.2.3.2 Deals
13.1.2.4 Analyst's view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 SAREPTA THERAPEUTICS, INC.
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches & approvals
13.1.3.3.2 Deals
13.1.3.4 Analyst's view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses & competitive threats
13.1.4 AMGEN, INC.
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Deals
13.1.4.4 Analyst's view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses & competitive threats
13.1.5 JOHNSON & JOHNSON
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Product approvals
13.1.5.3.2 Deals
13.1.5.4 Analyst's view
13.1.5.4.1 Key Strengths/Right to win
13.1.5.4.2 Strategic choices made
13.1.5.4.3 Weaknesses & competitive threats
13.1.6 BIOGEN INC.
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Product approvals
13.1.6.3.2 Expansions
13.1.7 SMITH+NEPHEW
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.8 MEDIPOST CO., LTD.
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Deals
13.1.8.3.2 Other developments
13.1.9 JCR PHARMACEUTICALS CO., LTD.
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.10 CORESTEM, INC.
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.10.3 Product pipeline
13.1.11 VERICEL CORPORATION
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.11.3 Recent developments
13.1.11.3.1 Product approvals
13.1.12 MIMEDX GROUP, INC.
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.12.3 Recent developments
13.1.12.3.1 Product launches
13.1.12.3.2 Deals
13.1.13 ORGANOGENESIS INC.
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.13.3 Recent developments
13.1.13.3.1 Deals
13.1.14 MEDTRONIC
13.1.14.1 Business overview
13.1.14.2 Products offered
13.1.14.3 Recent developments
13.1.14.3.1 Deals
13.1.15 BRISTOL-MYERS SQUIBB COMPANY
13.1.15.1 Business overview
13.1.15.2 Products offered
13.1.15.3 Recent developments
13.1.15.3.1 Product approvals
13.1.15.3.2 Deals
13.1.16 AUTOLUS THERAPEUTICS
13.1.16.1 Business overview
13.1.16.2 Products offered
13.1.16.3 Recent developments
13.1.16.3.1 Product approvals
13.1.16.3.2 Deals
13.2 OTHER PLAYERS
13.2.1 ORTHOCELL LTD.
13.2.2 MESOBLAST LTD.
13.2.3 BIORESTORATIVE THERAPIES, INC.
13.2.4 PLURISTEM THERAPEUTICS INC.
13.2.5 TEGOSCIENCE
13.2.6 ANTEROGEN. CO., LTD.
13.2.7 BLUEBIRD BIO, INC.
13.2.8 STEMPEUTICS RESEARCH PVT. LTD.
13.2.9 SIBIONO GENETECH CO. LTD.
13.2.10 ASPECT BIOSYSTEMS

14.1 RESEARCH DATA
14.1.1 SECONDARY DATA
14.1.2 PRIMARY DATA
14.2 MARKET SIZE ESTIMATION
14.2.1 PRIMARY INSIGHTS
14.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE MARKET
14.3 MARKET BREAKDOWN & DATA TRIANGULATION
14.4 STUDY ASSUMPTIONS
14.5 RISK ANALYSIS

15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: THE SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS

TABLE 1 REGENERATIVE MEDICINE MARKET: IMPACT ANALYSIS
TABLE 2 REGENERATIVE MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 REGENERATIVE MEDICINE MARKET: ROLE IN ECOSYSTEM
TABLE 4 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,2023-2025 (USD)
TABLE 5 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
TABLE 6 REGENERATIVE MEDICINE MARKET: KEY CONFERENCES & EVENTS, 2026-2027
TABLE 7 REDUCING CAR-T MANUFACTURING TURNAROUND TIME FOR YESCARTA
TABLE 8 EXPANDING CAR-T MANUFACTURING CAPACITY TO MEET GLOBALCARVYKTI DEMAND
TABLE 9 EXPANDING BIOMANUFACTURING CAPACITY FOR REGENERATIVETISSUE PRODUCTS
TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 11 INDICATIVE LIST OF PIPELINE PRODUCTS IN PHASE 3, 2025
TABLE 12 CASE STUDIES OF AI IMPLEMENTATION IN REGENERATIVE MEDICINE MARKET
TABLE 13 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN REGENERATIVEMEDICINE MARKET
TABLE 14 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,AND OTHER ORGANIZATIONS
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%)
TABLE 16 KEY BUYING CRITERIA, BY END USER
TABLE 17 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
TABLE 18 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 19 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION,2023-2031 (USD MILLION)
TABLE 20 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 21 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 22 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 23 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 24 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 25 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION,2023-2031 (USD MILLION)
TABLE 26 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 27 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 28 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 29 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 30 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2023-2031 (USD MILLION)
TABLE 31 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 32 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 33 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 34 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 35 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS,BY TYPE, 2023-2031 (USD MILLION)
TABLE 36 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS,BY REGION, 2023-2031 (USD MILLION)
TABLE 37 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 38 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 39 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 40 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 41 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2023-2031 (USD MILLION)
TABLE 42 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 43 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 44 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 45 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 46 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2023-2031 (USD MILLION)
TABLE 47 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 48 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 49 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 50 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 51 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY,BY REGION, 2023-2031 (USD MILLION)
TABLE 52 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 53 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 54 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 55 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 56 APPROVED GENE THERAPIES, 2022
TABLE 57 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION,2023-2031 (USD MILLION)
TABLE 58 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 59 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 60 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 61 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 62 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2023-2031 (USD MILLION)
TABLE 63 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 64 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 65 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 66 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 67 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 68 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS
TABLE 69 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION,2023-2031 (USD MILLION)
TABLE 70 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 71 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 72 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 73 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 74 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS,BY REGION, 2023-2031 (USD MILLION)
TABLE 75 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 76 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 77 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 78 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 79 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS
TABLE 80 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE,BY REGION, 2023-2031 (USD MILLION)
TABLE 81 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 82 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 83 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 84 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 85 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2031 (USD MILLION)
TABLE 86 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 87 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 88 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 89 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 90 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY
TABLE 91 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2023-2031 (USD MILLION)
TABLE 92 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 93 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 94 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 95 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 96 REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION,2023-2031 (USD MILLION)
TABLE 97 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 98 EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 99 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 100 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 101 REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023-2031 (USD MILLION)
TABLE 102 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 103 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 104 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 105 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 106 REGENERATIVE MEDICINE MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 107 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 108 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 109 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 110 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 111 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 112 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
TABLE 113 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
TABLE 114 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 115 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 116 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS,BY TYPE, 2023-2031 (USD MILLION)
TABLE 117 US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 118 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 119 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 120 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 122 CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 123 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 124 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 125 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 127 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 128 EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 129 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 130 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 131 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 133 GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 134 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
TABLE 135 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 136 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 137 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS,BY TYPE, 2023-2031 (USD MILLION)
TABLE 138 UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 139 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 140 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 141 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 143 FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 144 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 145 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 146 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 148 ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 149 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 150 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 151 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 153 SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 154 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 155 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 156 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 158 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
TABLE 159 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 160 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 162 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 163 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 164 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 165 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 166 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 167 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 169 CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 170 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 171 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 172 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 174 JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 175 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 176 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 177 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 179 INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 180 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 181 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 182 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 184 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
TABLE 185 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 186 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 187 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 189 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 190 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 191 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 192 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 194 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
TABLE 195 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 196 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 197 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 199 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 200 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
TABLE 201 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 202 BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 203 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 205 BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 206 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
TABLE 207 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 208 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 210 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
TABLE 211 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 212 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 213 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,BY TYPE, 2023-2031 (USD MILLION)
TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 215 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 216 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,2023-2031 (USD MILLION)
TABLE 217 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,2023-2031 (USD MILLION)
TABLE 218 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
TABLE 220 AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,2023-2031 (USD MILLION)
TABLE 221 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN THE REGENERATIVE MEDICINE MARKET
TABLE 222 REGENERATIVE MEDICINE MARKET: DEGREE OF COMPETITION
TABLE 223 REGENERATIVE MEDICINE MARKET: REGION FOOTPRINT
TABLE 224 REGENERATIVE MEDICINE MARKET: PRODUCT FOOTPRINT
TABLE 225 REGENERATIVE MEDICINE MARKET: THERAPEUTIC AREA FOOTPRINT
TABLE 226 REGENERATIVE MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 227 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 228 REGENERATIVE MEDICINE MARKET: PRODUCT LAUNCHES,JANUARY 2023-SEPTEMBER 2026
TABLE 229 REGENERATIVE MEDICINE MARKET: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 230 REGENERATIVE MEDICINE MARKET: EXPANSIONS, JANUARY2023-SEPTEMBER 2026
TABLE 231 NOVARTIS AG: COMPANY OVERVIEW
TABLE 232 NOVARTIS AG: PRODUCTS OFFERED
TABLE 233 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
TABLE 234 NOVARTIS AG: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 235 NOVARTIS AG: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
TABLE 236 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
TABLE 237 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
TABLE 238 GILEAD SCIENCES, INC.: PRODUCT APPROVALS,JANUARY 2023-SEPTEMBER 2026
TABLE 239 GILEAD SCIENCES, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 240 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 241 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 242 SAREPTA THERAPEUTICS, INC.: PRODUCT LAUNCHES & APPROVALS,JANUARY 2023-SEPTEMBER 2026
TABLE 243 SAREPTA THERAPEUTICS, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 244 AMGEN, INC.: COMPANY OVERVIEW
TABLE 245 AMGEN, INC.: PRODUCTS OFFERED
TABLE 246 AMGEN, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 247 JOHNSON & JOHNSON: COMPANY OVERVIEW
TABLE 248 JOHNSON & JOHNSON: PRODUCTS OFFERED
TABLE 249 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
TABLE 250 JOHNSON & JOHNSON: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 251 BIOGEN INC.: COMPANY OVERVIEW
TABLE 252 BIOGEN INC.: PRODUCTS OFFERED
TABLE 253 BIOGEN INC.: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
TABLE 254 BIOGEN INC.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
TABLE 255 SMITH+NEPHEW: COMPANY OVERVIEW
TABLE 256 SMITH+NEPHEW: PRODUCTS OFFERED
TABLE 257 MEDIPOST CO., LTD.: COMPANY OVERVIEW
TABLE 258 MEDIPOST: PRODUCTS OFFERED
TABLE 259 PRODUCT PIPELINE
TABLE 260 MEDIPOST: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 261 MEDIPOST: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
TABLE 262 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW
TABLE 263 JCR PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED
TABLE 264 CORESTEM, INC.: COMPANY OVERVIEW
TABLE 265 CORESTEM, INC.: PRODUCTS OFFERED
TABLE 266 VERICEL CORPORATION: COMPANY OVERVIEW
TABLE 267 VERICEL CORPORATION: PRODUCTS OFFERED
TABLE 268 VERICEL CORPORATION: PRODUCT APPROVALS,JANUARY 2023-SEPTEMBER 2026
TABLE 269 MIMEDX GROUP, INC.: COMPANY OVERVIEW
TABLE 270 MIMEDX GROUP, INC.: PRODUCTS OFFERED
TABLE 271 MIMEDX GROUP, INC.: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
TABLE 273 ORGANOGENESIS INC.: COMPANY OVERVIEW
TABLE 274 ORGANOGENESIS INC.: PRODUCTS OFFERED
TABLE 275 ORGANOGENESIS INC.: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
TABLE 276 MEDTRONIC: COMPANY OVERVIEW
TABLE 277 MEDTRONIC: PRODUCTS OFFERED
TABLE 278 MEDTRONIC: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
TABLE 279 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
TABLE 280 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
TABLE 281 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS,JANUARY 2023-SEPTEMBER 2026
TABLE 282 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 283 AUTOLUS THERAPEUTICS: COMPANY OVERVIEW
TABLE 284 AUTOLUS THERAPEUTICS: PRODUCTS OFFERED
TABLE 285 AUTOLUS THERAPEUTICS: PRODUCT APPROVALS,JANUARY 2023-SEPTEMBER 2026
TABLE 286 AUTOLUS THERAPEUTICS: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 287 ORTHOCELL LTD.: COMPANY OVERVIEW
TABLE 288 MESOBLAST LTD.: COMPANY OVERVIEW
TABLE 289 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW
TABLE 290 PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW
TABLE 291 TEGOSCIENCE: COMPANY OVERVIEW
TABLE 292 ANTEROGEN. CO., LTD.: COMPANY OVERVIEW
TABLE 293 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
TABLE 294 STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW
TABLE 295 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
TABLE 296 ASPECT BIOSYSTEMS: COMPANY OVERVIEW
TABLE 297 ATHERSYS, INC.: COMPANY OVERVIEW

FIGURE 1 REGENERATIVE MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 REGENERATIVE MEDICINE MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL REGENERATIVE MEDICINE MARKET, 2024-2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN REGENERATIVEMEDICINE MARKET, 2023-2026
FIGURE 6 DISRUPTIONS INFLUENCING THE GROWTH OF REGENERATIVE MEDICINE MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN REGENERATIVE MEDICINE MARKET, 2026-2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN REGENERATIVE MEDICINE MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 GROWING ADOPTION OF CELL & GENE THERAPY TO AID GROWTH
FIGURE 10 CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
FIGURE 11 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 12 CELL THERAPY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS,OPPORTUNITIES, AND CHALLENGES
FIGURE 14 REGENERATIVE MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 15 REGENERATIVE MEDICINE MARKET: VALUE CHAIN ANALYSIS
FIGURE 16 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS
FIGURE 17 REGENERATIVE MEDICINE MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 18 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
FIGURE 19 IMPACT OF AI/GEN AI ON REGENERATIVE MEDICINE MARKET
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
FIGURE 21 KEY BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS, BY END USER
FIGURE 22 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
FIGURE 23 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT
FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS, 2023-2025 (USD MILLION)
FIGURE 25 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 26 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX(KEY PLAYERS), 2025
FIGURE 27 REGENERATIVE MEDICINE MARKET: COMPANY FOOTPRINT
FIGURE 28 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 29 EV/EBITDA OF KEY PLAYERS
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCKBETA OF KEY PLAYERS
FIGURE 31 REGENERATIVE MEDICINES PRODUCTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF REGENERATIVE MEDICINES INSTRUMENTS
FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2025)
FIGURE 33 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 34 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2025)
FIGURE 35 AMGEN, INC.: COMPANY SNAPSHOT (2025)
FIGURE 36 JOHNSON & JOHNSON: COMPANY SNAPSHOT
FIGURE 37 BIOGEN INC.: COMPANY SNAPSHOT (2025)
FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2025)
FIGURE 39 MEDIPOST CO., LTD.: COMPANY SNAPSHOT (2023)
FIGURE 40 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 41 VERICEL CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 42 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2025)
FIGURE 43 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2025)
FIGURE 44 MEDTRONIC: COMPANY SNAPSHOT (2025)
FIGURE 45 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2025)
FIGURE 46 AUTOLUS THERAPEUTICS COMPANY: COMPANY SNAPSHOT (2025)
FIGURE 47 RESEARCH DESIGN
FIGURE 48 BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET
FIGURE 49 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS:REGENERATIVE MEDICINE MARKET, 2025
FIGURE 50 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2025
FIGURE 51 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2025
FIGURE 52 PRODUCT-BASED REVENUE ANALYSIS, 2025
FIGURE 53 VALIDATION FROM PRIMARY EXPERTS
FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 55 CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET
FIGURE 56 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET
FIGURE 57 DATA TRIANGULATION METHODOLOGY